SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE
SIREN 397866021
No insolvency procedure
No collective procedure published in the BODACC window loaded by Solvenda. Monitoring continues daily.
Index compliant
- Score published : 99/100 (edition 2025)
- Previous edition (2024) : 98/100
- Headcount band : 50 à 250
- Sector : Activités spécialisées, scientifiques et techniques
- Department : Sarthe
Source: Gender Equality Index published by the French Ministry of Labour, Open Licence 2.0. Absence from an edition may also mean the company left the obligation.
1 agreement(s) filed, 1 with a term date
| Agreement | Theme | Term |
|---|---|---|
| Egalité professionnelle entre les femmes et les hommes et qualité de vie au travail | Egalité salariale F/H | 1219 days (2029-12-31) |
Source: ACCO database of company agreements, DILA and Légifrance, Open Licence 2.0.
Solvenda watches for you, every morning.
Monitor this SIREN and your whole portfolio automatically.
Get started Risk index →Frequently asked questions
Is SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE in insolvency proceedings?
No collective procedure is published in the BODACC for SIREN 397866021 in the window loaded by Solvenda. This is not a solvency guarantee; monitoring continues daily.
Does the absence of a BODACC procedure guarantee solvency?
No. It only proves no insolvency procedure is published to date. Continuous monitoring by SIREN remains necessary.
What is the gender equality index of SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE?
SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE published a score of 99 for the 2025 edition. Below 75, a company has three years to correct, failing which a penalty of up to 1% of payroll may apply.
Does SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE have collective agreements?
1 company agreement(s) filed by SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE appear in the public ACCO database.